Drug intelligence / Profile preview

CLOX-315

Development stage: Unknown
Lead developer: Charleston Laboratories
Modality: Small Molecules
Administration: Oral

Overview

**CLOX-315** is an investigational fixed-dose oral combination of modified-release oxycodone and rapid-release promethazine developed by Charleston Laboratories for acute pain requiring opioid therapy and for prevention or reduction of opioid-induced nausea and vomiting. Oxycodone is a full agonist relatively selective for the mu-type opioid receptor and provides analgesia, while promethazine is an H1 receptor antagonist with antiemetic activity and relatively weak dopamine-receptor antagonist activity. The sponsor describes CLOX-315 as a formulation pairing rapid-release promethazine with modified-release oxycodone. ([charlestonlabs.com](https://charlestonlabs.com/pipeline/acute-pain/))

Other names: oxycodone + promethazinepromethazine + oxycodone

Targets

MOR (Mu opioid receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on CLOX-315.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLOX-315.

Explore the full profile